Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enpatoran - Merck KGaA

Next Previous
Search
Drug Profile

Enpatoran - Merck KGaA

Alternative Names: M-5049

Latest Information Update: 03 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono Research & Development Institute; Merck KGaA
  • Class Amines; Anti-inflammatories; Antivirals; Nitriles; Piperidines; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID-19 pneumonia; Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Systemic lupus erythematosus
  • No development reported Immunological disorders; Unspecified

Most Recent Events

  • 02 Dec 2024 Merck Healthcare KGaA completes a phase I trial (In volunteers) in Germany (PO) (NCT06589726) (EudraCT2024-512841-17-00)
  • 20 Nov 2024 Merck in collaboration with EMD Serono completes a phase II trial in Cutaneous lupus erythematosus in United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Greece, Israel, Japan, Mauritius, South Korea, Mexico, Moldova, Philippines, Poland, Romania, Serbia, South Africa, Taiwan, Spain (PO) (NCT05162586)
  • 30 Sep 2024 Merck Healthcare KGaA plans a pharmacokinetics phase I trial in healthy volunteers in Germany (PO) (NCT06589726) (EudraCT2024-512841-17-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top